|
US2020155650A1
|
|
Combination treatment of NAFLD and NASH
|
|
US2020155487A1
|
|
Treatment of obesity and its complications
|
|
CN111132675A
|
|
Treatment of cholestatic pruritus
|
|
US2019038581A1
|
|
Treatment of intrahepatic cholestatic diseases
|
|
EP3493807A1
|
|
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
|
US2017340589A1
|
|
Treatment of intrahepatic cholestatic diseases
|
|
WO2017200715A1
|
|
Treatment of severe hyperlipidemia
|
|
JP2017039762A
|
|
Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and second urate-lowering agent
|
|
JP2017061450A
|
|
Gouty redness therapeutic method
|
|
US2016279085A1
|
|
Treatment of Severe Hyperlipidemia
|
|
SG11201610243YA
|
|
Treatment of severe hypertriglyceridemia
|
|
UA121208C2
|
|
Treatment of nafld and nash
|
|
US2015258053A1
|
|
Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
|
|
WO2015143178A1
|
|
Treatment of intrahepatic cholestatic diseases
|
|
AU2014353246A1
|
|
Treatment of homozygous familial hypercholesterolemia
|
|
EA028495B1
|
|
Oral composition for treating gout based on (-)-halofenate and colchicine
|
|
NZ711096A
|
|
Dcc mediated coupling for halofenate manufacture
|
|
US2014128438A1
|
|
Methods for treating gout flares
|
|
KR20140121384A
|
|
Methods for treating gout flares
|
|
BR112014010693A2
|
|
use of a compound for the preparation of a pharmaceutical composition for the treatment of gout in subpopulations of patients
|
